Astragaloside IV attenuates podocyte apoptosis through ameliorating mitochondrial dysfunction by up-regulated Nrf2-ARE/TFAM signaling in diabetic kidney disease.

MLA

Shen, Qian, et al. “Astragaloside IV Attenuates Podocyte Apoptosis through Ameliorating Mitochondrial Dysfunction by Up-Regulated Nrf2-ARE/TFAM Signaling in Diabetic Kidney Disease.” Free Radical Biology & Medicine, vol. 203, July 2023, pp. 45–57. EBSCOhost, https://doi.org/10.1016/j.freeradbiomed.2023.03.022.

APA

Shen, Q., Fang, J., Guo, H., Su, X., Zhu, B., Yao, X., Wang, Y., Cao, A., Wang, H., & Wang, L. (2023). Astragaloside IV attenuates podocyte apoptosis through ameliorating mitochondrial dysfunction by up-regulated Nrf2-ARE/TFAM signaling in diabetic kidney disease. Free Radical Biology & Medicine, 203, 45–57. https://doi.org/10.1016/j.freeradbiomed.2023.03.022

Chicago

Shen, Qian, Ji Fang, Hengjiang Guo, Xue Su, Bingbing Zhu, Xingmei Yao, Yunman Wang, Aili Cao, Hao Wang, and Li Wang. 2023. “Astragaloside IV Attenuates Podocyte Apoptosis through Ameliorating Mitochondrial Dysfunction by Up-Regulated Nrf2-ARE/TFAM Signaling in Diabetic Kidney Disease.” Free Radical Biology & Medicine 203 (July): 45–57. doi:10.1016/j.freeradbiomed.2023.03.022.